L Holmes1,2,3,4, P Chavan5,6,7, T Blake5,6,8, K Dabney5,6. 1. Health Disparities Science Research Program, Office of Health Equity & Inclusion, Nemours Healthcare System for Children, 2200 Concord Pike, 7th floor, Wilmington, DE, 19803, USA. laurens.holmes@nemours.org. 2. Office of Health Equity and Inclusion, Health Disparities Science Research Section, Nemours/AIDHC, Wilmington, DE, 19803, USA. laurens.holmes@nemours.org. 3. Biological Sciences Department, University of Delaware, Newark, DE, 19716, USA. laurens.holmes@nemours.org. 4. Medical College of Wisconsin, Clinical & Translational Science Institute, Milwaukee, WI, 53226, USA. laurens.holmes@nemours.org. 5. Health Disparities Science Research Program, Office of Health Equity & Inclusion, Nemours Healthcare System for Children, 2200 Concord Pike, 7th floor, Wilmington, DE, 19803, USA. 6. Office of Health Equity and Inclusion, Health Disparities Science Research Section, Nemours/AIDHC, Wilmington, DE, 19803, USA. 7. Department of Epidemiology, Biostatistics and Environmental Health, University of Memphis School of Public Health, Memphis, TN, 38152, USA. 8. College of Health & Human Development, Penn State University, PA, 16802, State College, USA.
Abstract
BACKGROUND: While survival in overall pediatric malignancy has improved during recent decades, brain/central nervous system (CNS) tumors has not demonstrated comparable survival advantage. Incidence and mortality data in this malignancy continue to illustrate race and sex differences; however, there are few data in the pediatric setting. This study sought to characterize brain/CNS tumors by socio-demographic and assess racial and sex variances in both cumulative incidence and mortality. METHODS: A retrospective cohort design with Surveillance, Epidemiology and End Results (SEER) 1973-2014 was used for the assessment of children aged < 1-19 years diagnosed with brain/CNS tumors. The age-adjusted incidence rates were used for temporal trends, percent change, and annual percent change. We utilized binomial regression model to determine the exposure effect of race and sex on cancer mortality, adjusting for potential confounders. RESULTS: Childhood brain/CNS tumor cumulative incidence (CmI) continues to rise in annual percent change, and mortality varied by race, sex, and year of diagnosis. The CmI was highest among whites, intermediate among blacks, and lowest among Asians, as well as lower in females relative to that in males. Compared to whites, blacks were 21% more likely to die from brain/CNS tumors [risk ratio (RR) 1.21, 95% confidence interval (C.I.) 1.13-1.28], while males were 4% more likely to die relative to females (RR 1.04, 95% C.I. 1.00-1.08). After controlling for age, sex, and tumor grade, racial disparities persisted, with 16% increased risk of dying among blacks relative to whites [adjusted risk ratio 1.16, (99% C.I.) 1.08-1.25, p < 0.001]. CONCLUSION: The cumulative incidence of brain/CNS malignancy is higher among whites relative to that in blacks; however, blacks experienced survival disadvantage even after adjustment for potential tumor prognostic and predisposing factors.
BACKGROUND: While survival in overall pediatric malignancy has improved during recent decades, brain/central nervous system (CNS) tumors has not demonstrated comparable survival advantage. Incidence and mortality data in this malignancy continue to illustrate race and sex differences; however, there are few data in the pediatric setting. This study sought to characterize brain/CNS tumors by socio-demographic and assess racial and sex variances in both cumulative incidence and mortality. METHODS: A retrospective cohort design with Surveillance, Epidemiology and End Results (SEER) 1973-2014 was used for the assessment of children aged < 1-19 years diagnosed with brain/CNS tumors. The age-adjusted incidence rates were used for temporal trends, percent change, and annual percent change. We utilized binomial regression model to determine the exposure effect of race and sex on cancermortality, adjusting for potential confounders. RESULTS: Childhood brain/CNS tumor cumulative incidence (CmI) continues to rise in annual percent change, and mortality varied by race, sex, and year of diagnosis. The CmI was highest among whites, intermediate among blacks, and lowest among Asians, as well as lower in females relative to that in males. Compared to whites, blacks were 21% more likely to die from brain/CNS tumors [risk ratio (RR) 1.21, 95% confidence interval (C.I.) 1.13-1.28], while males were 4% more likely to die relative to females (RR 1.04, 95% C.I. 1.00-1.08). After controlling for age, sex, and tumor grade, racial disparities persisted, with 16% increased risk of dying among blacks relative to whites [adjusted risk ratio 1.16, (99% C.I.) 1.08-1.25, p < 0.001]. CONCLUSION: The cumulative incidence of brain/CNS malignancy is higher among whites relative to that in blacks; however, blacks experienced survival disadvantage even after adjustment for potential tumor prognostic and predisposing factors.
Entities:
Keywords:
Brain/CNS tumor; Childhood cancer; Health disparities; Pediatrics; Race and sex differences in cancer
Authors: Anne F Klassen; Samantha J Anthony; Aalia Khan; Lillian Sung; Robert Klaassen Journal: Support Care Cancer Date: 2011-05-25 Impact factor: 3.603
Authors: Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson Journal: J Pediatr Date: 2015-05-28 Impact factor: 4.406
Authors: Julia E Heck; Zuelma A Contreras; Andrew S Park; Tom B Davidson; Myles Cockburn; Beate Ritz Journal: Int J Cancer Date: 2016-04-15 Impact factor: 7.316
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167
Authors: Maral Adel Fahmideh; Erin C Peckham-Gregory; Jeremy M Schraw; Murali Chintagumpala; Stephen C Mack; Philip J Lupo; Michael E Scheurer Journal: Sci Rep Date: 2021-05-17 Impact factor: 4.379
Authors: Ha Son Nguyen; Ninh B Doan; Michael Gelsomino; Saman Shabani; Ahmed J Awad; Mayank Kaushal; Martin M Mortazavi Journal: Oncotarget Date: 2018-06-15